A new study from the University of Eastern Finland, published in the European Journal of Clinical Pharmacology, has highlighted that there are differences in the availability of orphan medicines between different European countries.
Europe
Orphan medicines are those developed specifically for the treatment, prevention or diagnostics of rare diseases, which are considered to be life-threatening or permanently disabling medical conditions that affect less than 5 in 10,000 of the general population.